IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: A case report

By Martinez-Redondo C.   Ortuño F.   Lozano M.   Jerez A.   del Mar Osma M.   Giraldo P.   Vicente V.  

Journal of Inherited Metabolic Disease, Vol. 32, Iss. 1, 2009-12 ,pp. : 265-267

Springer Publishing Company

Access to resources Recommend Favorite

Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy

By Marshall John   McEachern Kerry   Chuang Wei-Lien   Hutto Elizabeth   Siegel Craig   Shayman James   Grabowski Greg   Scheule Ronald   Copeland Diane   Cheng Seng  

Journal of Inherited Metabolic Disease, Vol. 33, Iss. 3, 2010-06 ,pp. : 281-289

Springer Publishing Company

Access to resources Recommend Favorite

COAGULATION ABNORMALITIES IN TYPE 1 GAUCHER DISEASE IN CHILDREN

By Deghady Akram   Marzouk Iman   El-Shayeb Ayman   Wali Yasseer  

Pediatric Hematology and Oncology, Vol. 23, Iss. 5, 2006-06 ,pp. : 411-417

Informa Healthcare

Access to resources Recommend Favorite

Lessons learned from the development of enzyme therapy for Gaucher disease

By Barranger J.   O'Rourke E.  

Journal of Inherited Metabolic Disease, Vol. 24, Iss. 2, 2001-04 ,pp. : 89-96

Springer Publishing Company

Access to resources Recommend Favorite

Clinically relevant therapeutic endpoints in type I Gaucher disease

By Hollak C.   Maas M.   Aerts J.  

Journal of Inherited Metabolic Disease, Vol. 24, Iss. 2, 2001-04 ,pp. : 97-105

Springer Publishing Company

Access to resources Recommend Favorite